Placebo - Cap: Clinical Trials

3 trials of Placebo - Cap, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 withdrawn. 3 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Completed 2, Withdrawn 1
Phase 21Completed 1

Follow Placebo - Cap: new trials by email Literature Review of Placebo - Cap trials Research Report on Placebo - Cap

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.
Dabigatran, Placebo - Cap - Mild Cognitive Impairment, Mild Alzheimer's Disease
Phase 1WithdrawnUniversity of Rhode Island2019-05-012025-04-17
INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers
Mifepristone, Placebo - Cap - Alcohol Use Disorder
Phase 1 / Phase 2CompletedJohns Hopkins University652017-09-262025-05-30
Pharmacological Modulation of Belief Salience
Placebo - Cap, L-dopa, Haloperidol - Haloperidol, Placebo
Phase 1CompletedKing's College London302017-06-012019-10-10

Conditions studied

Alcoholism (1)  ·  Cognitive Dysfunction (1)

Sponsors

Johns Hopkins University (1)  ·  King's College London (1)  ·  University of Rhode Island (1)

Countries

United Kingdom (1)  ·  United States (1)

Top investigators

John Stoukides, MD (1)  ·  Mary E McCaul, PhD (1)  ·  Paula Grammas, PhD (1)

Results publications

PMID 12505794, PMID 16929307, PMID 20057930

NIH funding

U01AA020890 (1)